In theory, SGLT-2 inhibitors should be considered before GLP-1RA because of the reduction in both CV and total deaths associated with their use
Metabolic pathways don't negotiate
Certain peptides control appetite and enhance metabolic rate, assisting in the reduction of excess abdominal fat
You may notice any of the following: Burning, tingling, or pain Numbness, decreased ability to feel pain or changes in temperature Muscle weakness or problems balancing or walking Serious foot problems, such as sores, infection, calluses, or bone and joint pain What do I need to know about DN screening
Safety note: Never use an online calculator to self-prescribe, change your dose, or replace pharmacy and provider instructions
and thyroid function tests to exclude anemia, renal disease, and electrolyte or thyroid disorders